HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beauty Firms Hit With Prop 65 Notice: Don’t Ignore Or Retailers May ‘Blackball’ You

Executive Summary

Ballard Spahr attorney Brendan Collins warned attendees to take Prop 65 violation notices seriously and address them in a timely manner, speaking at the Independent Beauty Association’s 2022 Technical Regulatory Forum.

You may also be interested in...

TiO2 Still A California Prop 65 Target; EU Commission Returns To SCCS With New Safety Questions

Titanium dioxide use in cosmetic products is getting another look by the EU’s Scientific Committee on Consumer Safety, with a focus on genotoxicity and exposure via inhalation and oral routes. Stateside, potentially respirable TiO2 continues to be the focus of Prop 65 lawsuits in California.

California Stretches Prop 65 Short-Form Warning Label Size But Sticks To Language Standard

Changes to proposed rule include increasing from 5 to 12 square inches the space allowed for a short-form warning, but use remains restricted to packages with limited available space for information that wouldn’t easily accommodate full warning. State’s accepting comments through 14 January.

Stakeholders Vie For California DTSC's Ear On Hair Straighteners, With Priority Product Pick Looming

Industry and consumer advocates typically differ in their views on the California Department of Toxic Substances Control’s Safer Consumer Products work, and the DTSC’s investigation into hair-straightening chemicals is no exception. In any event, a Priority Product selection could be coming soon.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts